Ljupcho Efremov

Dr. Ljupcho Efremov

Martin-Luther University Halle-Wittenberg, Medical Faculty, IMEBI
orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 September 2020 in Quality of Life Research
Verified
Journal Article
Open access
PDF file
DGDwi Gayatri
Dwi Gayatri
LELjupcho Efremov
Ljupcho Efremov
EKEva Johanna Kantelhardt
Eva Johanna Kantelhardt
RMRafael Mikolajczyk
Rafael Mikolajczyk
Purpose: This systematic review aims to summarize factors that influence the quality of life (QOL) of advanced cancer patients in palliative care (PC) in developing countries. Understanding this context in developing countries milieu is necessary; however, this outcome is rarely reported. Methods: Following the PRISMA guidelines, the electronic databases MEDLINE, Embase, CINAHL, and Web of Science were systematically searched using the search terms: QOL, cancer, PC, and names of all developing countries. Studies with less than ten subjects, qualitative or pilot studies, reviews, conference abstracts, and that reported validation of QOL questionnaires were excluded. Results: Fifty-five studies from 15 developing countries in the African (n = 5), Latin America and the Caribbean (n = 10), and Asian (n = 40) region were included in the narrative synthesis. 65.4% were cross-sectional, 27.3% were cohort studies, 7.3% were RCTs or quasi-experimental studies. Around 30 QOL factors were studied with 20 different types of QOL instruments. Advanced cancer patients who were older, married/ever married, participated in additional care within PC, used complementary and alternative medicine (CAM), and practiced spirituality/religiosity showed higher QOL score. Low educational level and high depression were associated with a lower QOL. Conclusion: Various factors affect QOL among cancer patients in PC. Patients valued the use of CAMs; however, the quality and safety aspects should be properly addressed. Important factors that influenced the QOL score were social and spiritual support. While there is a general need to develop PC strategies further, recognizing patients’ needs should be prioritized in national cancer programs.

5 November 2020 in Cochrane Database of Systematic Reviews
Verified
Journal Article
Closed access
PDF file
KUKonstantin Uhlig
Konstantin Uhlig
LELjupcho Efremov
Ljupcho Efremov
JTJörn Tongers
Jörn Tongers
SFStefan Frantz
Stefan Frantz
RMRafael Mikolajczyk
Rafael Mikolajczyk
Julia SchumannJulia Schumann
Julia Schumann

1 August 2015 in Journal of Clinical Microbiology
Verified
Journal Article
Closed access
PDF file
Brunella PosteraroBrunella Posteraro
Brunella Posteraro
LELjupcho Efremov
Ljupcho Efremov
ELEmanuele Leoncini
Emanuele Leoncini
RARosarita Amore
Rosarita Amore
PPPatrizia Posteraro
Patrizia Posteraro
Maurizio SanguinettiMaurizio Sanguinetti
Maurizio Sanguinetti
Accurate identification of pathogenic species is important for early appropriate patient management, but growing diversity of infectious species/strains makes the identification of clinical yeasts increasingly difficult. Among conventional methods that are commercially available, the API ID32C, AuxaColor, and Vitek 2 systems are currently the most used systems in routine clinical microbiology. We performed a systematic review and meta-analysis to estimate and to compare the accuracy of the three systems, in order to assess whether they are still of value for the species-level identification of medically relevant yeasts. After adopting rigorous selection criteria, we included 26 published studies involving Candida and non- Candida yeasts that were tested with the API ID32C (674 isolates), AuxaColor (1,740 isolates), and Vitek 2 (2,853 isolates) systems. The random-effects pooled identification ratios at the species level were 0.89 (95% confidence interval [CI], 0.80 to 0.95) for the API ID32C system, 0.89 (95% CI, 0.83 to 0.93) for the AuxaColor system, and 0.93 (95% CI, 0.89 to 0.96) for the Vitek 2 system ( P for heterogeneity, 0.255). Overall, the accuracy of studies using phenotypic analysis-based comparison methods was comparable to that of studies using molecular analysis-based comparison methods. Subanalysis of studies conducted on Candida yeasts showed that the Vitek 2 system was significantly more accurate (pooled ratio, 0.94 [95% CI, 0.85 to 0.99]) than the API ID32C system (pooled ratio, 0.84 [95% CI, 0.61 to 0.99]) and the AuxaColor system (pooled ratio, 0.76 [95% CI, 0.67 to 0.84]) with respect to uncommon species ( P for heterogeneity, <0.05). Subanalysis of studies conducted on non- Candida yeasts (i.e., Cryptococcus , Rhodotorula , Saccharomyces , and Trichosporon ) revealed pooled identification accuracies of ≥98% for the Vitek 2, API ID32C (excluding Cryptococcus ), and AuxaColor (only Rhodotorula ) systems, with significant low or null levels of heterogeneity ( P > 0.05). Nonetheless, clinical microbiologists should reconsider the usefulness of these systems, particularly in light of new diagnostic tools such as matrix-assisted laser desorption ionization–time of flight (MALDI-TOF) mass spectrometry, which allow for considerably shortened turnaround times and/or avoid the requirement for additional tests for species identity confirmation.

1 May 2017 in Journal of the American Heart Association
Verified
Journal Article
Open access
LJLotte Jacobs
Lotte Jacobs
LELjupcho Efremov
Ljupcho Efremov
JFJoao Pedro Ferreira
Joao Pedro Ferreira
LTLutgarde Thijs
Lutgarde Thijs
WYWen-Yi Yang
Wen-Yi Yang
NPNeil Poulter
Neil Poulter
Background: To address the need for personalized prevention, we conducted a subject‐level meta‐analysis within the framework of the Heart “OMics” in AGEing (HOMAGE) study to develop a risk prediction model for heart failure (HF) based on routinely available clinical measurements. Methods and Results: Three studies with elderly persons (Health Aging and Body Composition [Health ABC], Valutazione della PREvalenza di DIsfunzione Cardiaca asinTOmatica e di scompenso cardiaco [PREDICTOR], and Prospective Study of Pravastatin in the Elderly at Risk [PROSPER]) were included to develop the HF risk function, while a fourth study (Anglo‐Scandinavian Cardiac Outcomes Trial [ASCOT]) was used as a validation cohort. Time‐to‐event analysis was conducted using the Cox proportional hazard model. Incident HF was defined as HF hospitalization. The Cox regression model was evaluated for its discriminatory performance (area under the receiver operating characteristic curve) and calibration (Grønnesby‐Borgan χ 2 statistic). During a follow‐up of 3.5 years, 470 of 10 236 elderly persons (mean age, 74.5 years; 51.3% women) developed HF . Higher age, BMI, systolic blood pressure, heart rate, serum creatinine, smoking, diabetes mellitus, history of coronary artery disease, and use of antihypertensive medication were associated with increased HF risk. The area under the receiver operating characteristic curve of the model was 0.71, with a good calibration (χ 2 7.9, P =0.54). A web‐based calculator was developed to allow easy calculations of the HF risk. Conclusions: Simple measurements allow reliable estimation of the short‐term HF risk in populations and patients. The risk model may aid in risk stratification and future HF prevention strategies.

9 September 2023 in Nutrition, Metabolism and Cardiovascular Diseases
Verified
Journal Article
Open access
ZSZhouli Su
Zhouli Su
LELjupcho Efremov
Ljupcho Efremov
RMRafael Mikolajczyk
Rafael Mikolajczyk
The aim of this study was to systematically review and analyze differences in the levels of C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α) comparing metabolically healthy but obese (MHO) with metabolically healthy non-obese (MHNO), metabolically unhealthy non-obese (MUNO), and metabolically unhealthy obese (MUO) subjects. We searched PubMed, Embase, Web of Science, and Scopus for studies that matched the relevant search terms. Differences in inflammatory marker levels between MHO and the other three phenotypes were pooled as standardized mean differences (SMD) or differences of medians (DM) using a random-effects model. We included 91 studies reporting data on 435,106 individuals. The CRP levels were higher in MHO than in MHNO subjects (SMD = 0.63, 95% CI: 0.49, 0.77; DM = 0.91 mg/L, 95% CI: 0.58, 1.24). The CRP levels were higher in MHO than in MUNO subjects (SMD = 0.17, 95% CI: 0.05, 0.28; DM = 0.44 mg/L, 95% CI: 0.10, 0.78). The CRP levels were lower in MHO than in MUO individuals (SMD = -0.43, 95% CI: -0.54, -0.31; DM = -0.83 mg/L, 95% CI: -1.18, -0.47). The IL-6 levels were lower in MHO than in MUO subjects. The TNF-α levels in MHO were higher than in MHNO individuals. This review provides evidence that CRP levels in MHO are higher than in MHNO and MUNO subjects but lower than in MUO individuals. Additionally, IL-6 levels in MHO are lower than in MUO subjects, and TNF-α levels in MHO are higher than in MHNO individuals. PROSPERO number: CRD42021234948.

20 March 2021 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Open access
PDF file
LELjupcho Efremov
Ljupcho Efremov
SASemaw Ferede Abera
Semaw Ferede Abera
ABAhmed Bedir
Ahmed Bedir
DVDirk Vordermark
Dirk Vordermark
DMDaniel Medenwald
Daniel Medenwald
Introduction: Glioblastoma multiforme (GBM) is a primary malignant brain tumour characterized by a very low long-term survival. The aim of this study was to analyse the distribution of treatment modalities and their effect on survival for GBM cases diagnosed in Germany between 1999 and 2014. Methods: Cases were pooled from the German Cancer Registries with International Classification of Diseases for Oncology, third edition (ICD-O-3) codes for GBM or giant-cell GBM. Three periods, first (January 1999–December 2005), second (January 2006–December 2010) and a third period (January 2011–December 2014) were defined. Kaplan–Meier plots with long-rank test compared median overall survival (OS) between groups. Survival differences were assessed with Cox proportional-hazards models adjusted for available confounders. Results: In total, 40,138 adult GBM cases were analysed, with a mean age at diagnosis 64.0 ± 12.4 years. GBM was more common in men (57.3%). The median OS was 10.0 (95% CI 9.0–10.0) months. There was an increase in 2-year survival, from 16.6% in the first to 19.3% in the third period. When stratified by age group, period and treatment modalities, there was an improved median OS after 2005 due to treatment advancements. Younger age, female sex, surgical resection, use of radiotherapy and chemotherapy, were independent factors associated with better survival. Conclusion: The inclusion of temozolomide chemotherapy has considerably improved median OS in the older age groups but had a lesser effect in the younger age group of cases. The analysis showed survival improvements for each treatment option over time.